Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
34.98%
Grew
—
—
Shrank
—
1 Year
Score—
Net Growth34.98%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
—
-52.35%
60%
—
—
Never
—
5 Years
Score—
Net Growth-52.35%
Net Trend60%
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
Chemomab Therapeutics Ltd DRC fundamental performance
Across Chemomab Therapeutics Ltd DRC's full reported history, from 2019 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from $ 27M to -$ 9M. Revenue increased in 0% of the years measured; net income in 50%.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 1.92 | — |
1 Year2025-08-12 | $ 3.70 | -48.11% |
5 Years2021-08-12 | $ 64.68 | -97.03% |
All Time2019-02-12 | $ 691.20 | -99.72% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-02-12 |
|---|---|---|---|---|
| Price | $ 1.92 | $ 3.70 | $ 64.68 | $ 691.20 |
| Return | — | -48.11% | -97.03% | -99.72% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 0.00 | -$ 9M | $ 10M |
| 2024 | $ 0.00 | -$ 13M | $ 14M |
| 2023 | $ 0.00 | -$ 24M | $ 19M |
| 2022 | $ 0.00 | -$ 27M | $ 39M |
| 2021 | $ 0.00 | -$ 12M | $ 61M |
| 2020 | $ 0.00 | -$ 5M | $ 11M |
| IPO2019 | $ 0.00 | $ 27M | $ 17M |
Explore beyond CMMB
You're looking at Chemomab Therapeutics Ltd DRC. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
